SUMMARY The antigonococcal activity of the quinolone derivative flumequine was evaluated. Of 246 strains examined, 240 (97* 5%) strains showed minimum inhibitory concentrations (MICs) of flumequine of <0 4 .g/ml, including three P-lactamase-producing strains. The six remaining strains showed MICs from 3 -2 to 9 6 .g/ml. By disc diffusion tests using 3-14g discs of flumequine the zones of growth inhibition correlated well with the MICs of flumequine.
Introduction
Flumequine is a synthetic antibacterial agent for oral use. It is a quinolone derivative and is thus structurally related to nalidixic acid, oxolonic acid, and rosoxacin. Like these drugs its antibacterial activity, which is bactericidal, is mostly directed against Gram-negative bacteria. Flumequine is well absorbed after oral administration which results in therapeutic concentrations in serum, tissues, and body fluids including urine. This drug has been used for the treatment of urinary tract infections (Riker Laboratories Ltd, unpublished data).
Gonorrhoea which is resistant to treatment with penicillins occurs with variable frequency in different parts of the world. Thus, 28 8%7o of gonococci isolated in Singapore in 1980 were resistant due to production of P-lactamase. l Penicillin-resistant gonococci frequently show reduced susceptibility to a number of other antimicrobial agents.2 Gonococci producing P-lactamase have been reported to be resistant to spectinomycin. 4 This emphasises the importance of evaluating alternatives to the antimicrobial agents currently used for the treatment of gonorrhoea. The 
Patients and methods
Volunteers for enrolment into the study were women and men over 16 years of age attending the outpatient clinic for venereal diseases at the University Hospital, Trondheim, during 1981. All the patients had uncomplicated gonorrhoea, verified by examination of smears and by culture. Pregnant women were excluded from the study.
DIAGNOSIS
Gram-stained smears of material from the urethra of male patients and from the urethra and cervix of female patients were examined. Specimens for culture of gonococci were taken from the urethra of men and the urethra, cervix, and rectum of women using charcoal-impregnated swabs and Stuart's transport medium. Occasionally specimens for culture were taken from the oropharynx or from the rectum of homosexual men. The specimens were plated the same day on a modified New York City medium. For disc diffusion testing chocolate agar plates were flooded with the bacterial suspension to give semiconfluent growth. The plates were air-dried, and paper discs (Oxoid, England) impregnated with 3 Mg of flumequine were applied. The diameter of the zone of inhibition was measured after incubation in a candle jar at 37°C for 48 hours.
TREATMENT WITH FLUMEQUINE
The patients were assigned to three groups according to three dosage regimens: (A): flumequine 1200, 800, and 800 mg (three doses) orally at six hourly intervals; (B): flumequine 1200 and 800 mg (two doses) at six hourly intervals; and (C): flumequine in a single dose of 1200 mg.
FOLLOW-UP EXAMINATION
The patients were examined by microscopy of smears and by culture at one and two-weeks respectively after treatment. At the follow-up examination the patients were asked for any possible side effects.
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IN-VITRO SENSITIVITY TESTS
All of the 246 primary gonococcal isolates from the patients under study were examined for their MICs of flumequine and 172 of the strains by the disc diffusion method. MICs of flumequine ranged from 0 05 to 9-6 Mg/ml with a mean value of 0 16 pg/ml (table I) . The strains showed a bimodal distribution for MICs. MICs of .0 4 Ag/ml were recorded for 97 607% of the isolates with a peak number of strains at 0 1,ug/ml; 2 4%o of the strains had MICs of >3 * 2 lAg/ml.
The correlation between flumequine MICs and the diameter of the inhibition zones measured on disc diffusion testing of the gonococci is shown in the figure. The inverse correlation was good (r = -0-885, P<0 01; least squares method). An MIC of 0-4 Ag/ml was defined as the breakpoint between sensitive strains and those showing reduced sensitivity to flumequine, this value corresponded to an inhibition zone of 28 mm in diameter using discs containing 3 Mg of the drug. The failures (10 male patients) included all of the six patients who were infected with strains of gonococci having flumequine MICs of 3-2 jig/ml. Flumequine-sensitive gonococci on primary culture and resistant strains at the first follow-up examination were recorded in two of the failures. Gonococci sensitive to flumequine were isolated from the remaining two failures, both before and after treatment.
SIDE EFFECTS
Side effects were noted by 14-607o of the patients (table III) (22v 1%o of the women and 9-7% of the men). They were mostly vague in character, appeared shortly after the first dose of flumequine, lasted for 4-6 hours, and were described mostly as dizziness and in a few patients as confusion. The side effects did not prevent patients completing treatment except for one woman who had minor neurological disturbances.
Discussion
The present study has shown that 97-6% of gonococci isolated from patients in our community before treatment of the infection were sensitive to flumequine. 3 In the present study MICs of flumequine were not correlated with those of other antibiotics. All the patients infected with flumequine-resistant gonococci were, however, cured by treatment with pivampicillin. All three gonococcal isolates producing P-lactamase were susceptible to flumequine and the patients infected with these bacteria were cured with this drug.
The efficacy of antimicrobial agents in the treatment of gonorrhoea is obviously related to the MICs for the infecting strains.'°Clearly, this was also the case with flumequine. The dosage regimens A and B resulted in an overall cure rate of 98070 of the patients infected with gonococci with MICs (0-4 0 g/ml. None of the patients with gonococci with MICs >3 3 tg/ml were cured. The two-dose regimen of flumequine was fully effective whereas the singledose regimen was not. Thus, eradication of gonococci requires therapeutic serum concentrations of flumequine for several hours. The two-dose regimen resulted in the cure of patients with rectal gonorrhoea, including one homosexual man. All of the failures were male patients. The reason for this has not been fully explained. The primary isolates showing flumequine resistance may, however, have originated from the same two infection sources. Prolonged treatment of these patients, even with higher doses of flumequine, did not result in cure.
Side effects of flumequine were noted by 14-6%o of the patients, mostly women. The side effects resembled those observed with nalidixic acidtI and rosoxacint2 and suggest neurotoxicity. Severe side effects, however, were noted in only one patient. Nevertheless, the effects observed warrant advice against certain activities, such as car driving, for at least six hours after the first dose.
Studies not yet completed have shown that the occurrence of adverse reactions can be reduced by adjusting the dosage according to body weight without reducing the efficacy of the drug in the treatment of gonorrhoea.
Facilities for the culture of Chiamydia trachomatis were available only for the last month of the study. During this time five of the male patients developed postgonococcal urethritis after cure for gonorrhoea by treatment with flumequine. Chlamydia was isolated from the urethra of all of these patients. All of these patients received the two-dose regimen and the results are in contrast to those observed clinically in patients receiving the three-dose regimen, in whom no cases of post-gonococcal urethritis occurred. 
